版本:
中国

BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)

June 2 Bristol-Myers Squibb Co:

* European Commission approves Bristol-Myers Squibb’s opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy

* Bristol-Myers Squibb Co - ‍opdivo is now approved in european union for eight indications in six distinct tumor types​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐